Browsing Tag
Brent Saunders
6 posts
Bausch + Lomb (NYSE: BLCO) names Thomas Appio interim CEO as Saunders departs
Bausch + Lomb Corporation has replaced Chief Executive Officer Brent Saunders with Chairman Thomas Appio on an interim basis after Saunders and the board mutually agreed on his departure. The leadership change arrives just as preliminary third-quarter results point to another improvement in 2026 adjusted EBITDA guidance, creating an unusual contrast between stronger operating momentum and an abrupt change at the top.
Bausch + Lomb completes credit agreement amendment, reducing interest cost on $2.8bn debt
Find out how Bausch + Lomb’s $2.8B refinancing plan reshapes its debt profile, reduces interest margins, and defers amortization until 2026.
Bausch + Lomb completes XIIDRA acquisition to fortify dry eye offering
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition…
Bausch + Lomb to acquire dry eye disease medication XIIDRA from Novartis
Bausch + Lomb has reached a definitive agreement with Novartis to acquire the non-steroid eye drop XIIDRA (lifitegrast…
AbbVie acquisition of Allergan gets antitrust clearance from US FTC
AbbVie acquisition of Allergan update : US biopharma company AbbVie has secured clearance from the US Federal Trade…
Allergan to acquire Bonti in strategic $195m deal to expand medical aesthetics pipeline
Irish pharmaceutical giant Allergan has announced its acquisition of Bonti, a U.S.-based aesthetic company specializing in fast-acting neurotoxin…